Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 6800 (miR-6800, hsa-miR-6800) is a member of the microRNA family, a class of small non-coding RNAs (~22 nucleotides) that post-transcriptionally regulate gene expression by pairing with target mRNAs, often resulting in their degradation or repression of translation. miR-6800 has been identified in circulating extracellular vesicles and is reported in computational and biomarker studies as being differentially expressed in several human cancers such as colorectal, ovarian, and prostate cancer, where it may serve as a diagnostic biomarker for disease subtype classification and early detection[1][2]. There are no direct reports of drugs acting on miR-6800, nor evidence for its use as a druggable therapeutic target. Thus, while it shows potential as a cancer biomarker, it is not a canonical drug target or receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 6800 (miR-6800).